Cassava Sciences (FLNA) Competitors $1.31 +0.02 (+1.55%) As of 05/22/2026 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FLNA vs. HELP, ALEC, NERV, CHRS, and CNTNShould you buy Cassava Sciences stock or one of its competitors? MarketBeat compares Cassava Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cassava Sciences include Cybin (HELP), Alector (ALEC), Minerva Neurosciences (NERV), Coherus Oncology (CHRS), and Hillstream Biopharma (CNTN). These companies are all part of the "pharmaceutical products" industry. FLNA vs. HELPFLNA vs. ALECFLNA vs. NERVFLNA vs. CHRSFLNA vs. CNTNHow does Cassava Sciences compare to Cybin?Cassava Sciences (NASDAQ:FLNA) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Does the media refer more to FLNA or HELP? In the previous week, Cassava Sciences' average media sentiment score of 0.00 equaled Cybin'saverage media sentiment score. Company Overall Sentiment Cassava Sciences Neutral Cybin Neutral Do analysts prefer FLNA or HELP? Cybin has a consensus price target of $58.75, indicating a potential upside of 1,155.34%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cybin 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in FLNA or HELP? 38.1% of Cassava Sciences shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk and volatility, FLNA or HELP? Cassava Sciences has a beta of -0.75, meaning that its share price is 175% less volatile than the broader market. Comparatively, Cybin has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Is FLNA or HELP more profitable? Cassava Sciences' return on equity of -53.90% beat Cybin's return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -53.90% -34.20% Cybin N/A -59.98%-50.80% Which has better valuation & earnings, FLNA or HELP? Cybin is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$90.97M-$1.61N/ACybinN/AN/A-$81.31M-$4.23N/A SummaryCybin beats Cassava Sciences on 6 of the 11 factors compared between the two stocks.How does Cassava Sciences compare to Alector?Alector (NASDAQ:ALEC) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Do insiders and institutionals hold more shares of ALEC or FLNA? 85.8% of Alector shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 8.3% of Alector shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, ALEC or FLNA? Alector has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market. Which has higher earnings & valuation, ALEC or FLNA? Cassava Sciences has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlector$21.05M11.66-$142.93M-$1.19N/ACassava SciencesN/AN/A-$90.97M-$1.61N/A Does the media refer more to ALEC or FLNA? In the previous week, Alector's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score. Company Overall Sentiment Alector Neutral Cassava Sciences Neutral Is ALEC or FLNA more profitable? Cassava Sciences has a net margin of 0.00% compared to Alector's net margin of -680.83%. Cassava Sciences' return on equity of -53.90% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alector-680.83% -295.17% -40.95% Cassava Sciences N/A -53.90%-34.20% Do analysts recommend ALEC or FLNA? Alector currently has a consensus target price of $3.63, indicating a potential upside of 64.03%. Given Alector's stronger consensus rating and higher possible upside, research analysts plainly believe Alector is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alector 2 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.13Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryAlector beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.How does Cassava Sciences compare to Minerva Neurosciences?Minerva Neurosciences (NASDAQ:NERV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Do insiders and institutionals have more ownership in NERV or FLNA? 34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to NERV or FLNA? In the previous week, Minerva Neurosciences had 11 more articles in the media than Cassava Sciences. MarketBeat recorded 11 mentions for Minerva Neurosciences and 0 mentions for Cassava Sciences. Minerva Neurosciences' average media sentiment score of 0.74 beat Cassava Sciences' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Overall Sentiment Minerva Neurosciences Positive Cassava Sciences Neutral Do analysts recommend NERV or FLNA? Minerva Neurosciences currently has a consensus target price of $10.50, suggesting a potential upside of 99.62%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Minerva Neurosciences is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more risk and volatility, NERV or FLNA? Minerva Neurosciences has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market. Which has higher valuation and earnings, NERV or FLNA? Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMinerva NeurosciencesN/AN/A-$293.42M-$29.16N/ACassava SciencesN/AN/A-$90.97M-$1.61N/A Is NERV or FLNA more profitable? Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Minerva NeurosciencesN/A N/A -32.63% Cassava Sciences N/A -53.90%-34.20% SummaryMinerva Neurosciences beats Cassava Sciences on 10 of the 13 factors compared between the two stocks.How does Cassava Sciences compare to Coherus Oncology?Coherus Oncology (NASDAQ:CHRS) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation. Do analysts rate CHRS or FLNA? Coherus Oncology presently has a consensus target price of $8.67, indicating a potential upside of 438.30%. Given Coherus Oncology's stronger consensus rating and higher probable upside, research analysts plainly believe Coherus Oncology is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Does the media prefer CHRS or FLNA? In the previous week, Coherus Oncology's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score. Company Overall Sentiment Coherus Oncology Neutral Cassava Sciences Neutral Which has more volatility & risk, CHRS or FLNA? Coherus Oncology has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, indicating that its stock price is 175% less volatile than the broader market. Is CHRS or FLNA more profitable? Coherus Oncology has a net margin of 397.30% compared to Cassava Sciences' net margin of 0.00%. Cassava Sciences' return on equity of -53.90% beat Coherus Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Coherus Oncology397.30% -198.90% -46.65% Cassava Sciences N/A -53.90%-34.20% Do insiders & institutionals believe in CHRS or FLNA? 72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable valuation and earnings, CHRS or FLNA? Coherus Oncology has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$42.17M5.89$168.02M$1.670.96Cassava SciencesN/AN/A-$90.97M-$1.61N/A SummaryCoherus Oncology beats Cassava Sciences on 11 of the 13 factors compared between the two stocks.How does Cassava Sciences compare to Hillstream Biopharma?Hillstream Biopharma (NASDAQ:CNTN) and Cassava Sciences (NASDAQ:FLNA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk. Does the media favor CNTN or FLNA? In the previous week, Hillstream Biopharma had 2 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Hillstream Biopharma and 0 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.18 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Overall Sentiment Hillstream Biopharma Neutral Cassava Sciences Neutral Which has higher valuation & earnings, CNTN or FLNA? Hillstream Biopharma is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHillstream BiopharmaN/AN/A-$35.92M-$1.15N/ACassava SciencesN/AN/A-$90.97M-$1.61N/A Which has more volatility & risk, CNTN or FLNA? Hillstream Biopharma has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.75, meaning that its stock price is 175% less volatile than the broader market. Do insiders and institutionals hold more shares of CNTN or FLNA? 1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is CNTN or FLNA more profitable? Hillstream Biopharma's return on equity of -31.50% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Hillstream BiopharmaN/A -31.50% -24.72% Cassava Sciences N/A -53.90%-34.20% Do analysts prefer CNTN or FLNA? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryHillstream Biopharma beats Cassava Sciences on 7 of the 10 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for FLNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FLNA vs. The Competition ExportMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$63.28M$3.04B$6.44B$12.34BDividend YieldN/A1.97%2.76%5.28%P/E Ratio-0.8118.0421.2625.66Price / SalesN/A358.13556.8487.32Price / CashN/A57.7443.6856.73Price / Book0.935.8610.367.14Net Income-$90.97M$74.99M$3.56B$335.80M7 Day Performance11.02%0.37%5.12%3.02%1 Month Performance-18.63%-2.99%3.54%2.48%1 Year Performance-37.91%34.38%34.14%35.08% Cassava Sciences Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FLNACassava Sciences0.132 of 5 stars$1.31+1.6%N/A-37.9%$63.28MN/AN/A20HELPCybin3.1209 of 5 stars$4.54-2.8%$58.75+1,194.1%N/A$234.40MN/AN/A50Positive NewsGap UpALECAlector3.0948 of 5 stars$2.11-2.5%$3.63+72.2%+78.2%$233.72M$21.05MN/A270NERVMinerva Neurosciences2.5725 of 5 stars$4.99-4.3%$10.50+110.5%+260.3%$232.34MN/AN/A9Positive NewsAnalyst RevisionGap UpCHRSCoherus Oncology2.5423 of 5 stars$1.51-4.1%$8.67+475.9%+112.9%$232.15M$42.17M0.90330 Related Companies and Tools Related Companies Cybin Competitors Alector Competitors Minerva Neurosciences Competitors Coherus Oncology Competitors Hillstream Biopharma Competitors Whitehawk Therapeutics Competitors Entrada Therapeutics Competitors Tonix Pharmaceuticals Competitors Foghorn Therapeutics Competitors Artiva Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FLNA) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
